Skip to content

Cronos Group

US · CRON #3133 by market cap Listed 1970
3.24 -0.05 -1.37%
Live - 5344 symbols - heartbeat 168s ago · 2026-10-08 05:42
Pre-market 3.19 -1.51%
After-hours 3.25 +0.31%
Market cap
1.19B
P/B
1.12
EPS
-0.02
Reader sentiment Are you bullish or bearish on CRON?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 1.13 Expensive vs history 96th percentile
5-year average 0.83 · #27 of 70 in Drug Manufacturers - Specialty & Generic
P/E ratio 17.29 Expensive vs history 87th percentile
5-year average -5.23 · forward 24.39 · #11 of 25 in Drug Manufacturers - Specialty & Generic
P/S ratio 6.76 Cheap vs history 21st percentile
5-year average 10.48 · forward 6.70 · #62 of 80 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Cronos Group (CRON) 1.19B 17.05 1.12 0.00%
Takeda Pharmaceutical (TAK) 58.68B -55.67 1.23 3.26%
Teva Pharmaceutical Industries (TEVA) 45.70B 65.30 5.89 0.00%
Haleon (HLN) 39.67B 18.87 1.83 2.11%
Zoetis (ZTS) 29.57B 11.67 9.39 2.88%
United Therapeutics (UTHR) 23.38B 19.53 3.65 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value3.62 Economic moatNone UncertaintyMedium

Trading 11.6% below Morningstar's fair value estimate.

Fair value

Cronos Group Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $3.61 per share; however, some caution is warranted due to this estimate's medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 89.4%, which lies in the top 40% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 14.6%, a core component of profitability, sits in the bottom 20% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-10-08 05:42:01 · For reference only, not investment advice and not tailored to your situation.